| 前收市價 | 5.15 |
| 開市 | 5.15 |
| 買盤 | 5.10 |
| 賣出價 | 5.30 |
| 拍板 | 125.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 5.15 - 5.15 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2.73k |
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
ZacksHere's Why Merck (MRK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BenzingaMerck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb
